Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH005
S. Ponnusamy, Yaashikaa Ponnambalam Ragini
The composite of the present pharmaceutical industry requires more effective medication improvement and generation. A product lifecycle (PLC) is the progression of stages from the product's production to the world until its last withdrawal from the market. Product lifecycle comprises various stages that a product must possess in its lifespan, for example, launching, growth, maturity, and decline stage. While each stage brings huge changes, a progression of procedures for the administration of product lifecycle is required. Product lifecycle management (PLM) is a precise, controlled idea for overseeing and creating products and product-related data. Enhanced patient consistency, income development, extended clinical advantages, and faster market dispatch are among the primary utilization of product lifecycle management. To create a viable and productive product lifecycle management program many qualities are viewed like promising start, vital arranging clear authority, supporting information and abilities, readiness for changing tenets of government and associations.
{"title":"Product Lifecycle in the Pharmaceutical Industry","authors":"S. Ponnusamy, Yaashikaa Ponnambalam Ragini","doi":"10.4018/978-1-5225-5921-4.CH005","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH005","url":null,"abstract":"The composite of the present pharmaceutical industry requires more effective medication improvement and generation. A product lifecycle (PLC) is the progression of stages from the product's production to the world until its last withdrawal from the market. Product lifecycle comprises various stages that a product must possess in its lifespan, for example, launching, growth, maturity, and decline stage. While each stage brings huge changes, a progression of procedures for the administration of product lifecycle is required. Product lifecycle management (PLM) is a precise, controlled idea for overseeing and creating products and product-related data. Enhanced patient consistency, income development, extended clinical advantages, and faster market dispatch are among the primary utilization of product lifecycle management. To create a viable and productive product lifecycle management program many qualities are viewed like promising start, vital arranging clear authority, supporting information and abilities, readiness for changing tenets of government and associations.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124112472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH014
J. Vargas-Hérnandez, Alma Isela Rodríguez Hernández
The objective of this chapter is to analyze the collaboration networks of the Mexican pharmaceutical industry from an institutional approach. The pharmaceutical sector at a global level is characterized by a high dynamism in innovation and collaboration. One could say that the high value recorded by the industry is due to this. However, in Mexico, the lack of efficient institutions that ensure the appropriation of profits for investment in research within the industry is not perceived; this situation leads us to the next question, What are the dynamics of collaboration between pharmaceutical companies in Mexico? To answer this question, a database was created that identifies the alliances of the companies belonging to the Canifarma. Finally, a comparison of the number of registrations and patent applications between eight of these companies is made to measure the results of this situation.
{"title":"Collaboration in the Mexican Pharmaceutical Industry","authors":"J. Vargas-Hérnandez, Alma Isela Rodríguez Hernández","doi":"10.4018/978-1-5225-5921-4.CH014","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH014","url":null,"abstract":"The objective of this chapter is to analyze the collaboration networks of the Mexican pharmaceutical industry from an institutional approach. The pharmaceutical sector at a global level is characterized by a high dynamism in innovation and collaboration. One could say that the high value recorded by the industry is due to this. However, in Mexico, the lack of efficient institutions that ensure the appropriation of profits for investment in research within the industry is not perceived; this situation leads us to the next question, What are the dynamics of collaboration between pharmaceutical companies in Mexico? To answer this question, a database was created that identifies the alliances of the companies belonging to the Canifarma. Finally, a comparison of the number of registrations and patent applications between eight of these companies is made to measure the results of this situation.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126211508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4018/978-1-5225-5921-4.CH008
S. Ponnusamy, A. Saravanan
The pharmaceutical supply chain is presently a noteworthy research topic in process operations and administration. A lot of research has been embraced on office area and configuration, stock and circulation arranging, limit and generation arranging, and point-by-point planning. Just a little extent of this work straightforwardly addresses the issues confronted in the pharmaceutical division. The pharmaceutical industry is facing extraordinary difficulties caused by a maturing population, the expanding expense of medicinal services, the priority given by the governments to bring down the cost of medications, boundaries to a passage in developing markets, and the more extensive reception of non-specific medications. These are quite recently a portion of the many difficulties making weight on the overall revenue of pharmaceutical firms. Expanded expenses of R&D and a diminished number of affirmed sedates additionally demonstrates that the lion's share of prescription, which is anything but difficult to find, has just been found.
{"title":"Characteristics of Pharmaceutical Supply Chains","authors":"S. Ponnusamy, A. Saravanan","doi":"10.4018/978-1-5225-5921-4.CH008","DOIUrl":"https://doi.org/10.4018/978-1-5225-5921-4.CH008","url":null,"abstract":"The pharmaceutical supply chain is presently a noteworthy research topic in process operations and administration. A lot of research has been embraced on office area and configuration, stock and circulation arranging, limit and generation arranging, and point-by-point planning. Just a little extent of this work straightforwardly addresses the issues confronted in the pharmaceutical division. The pharmaceutical industry is facing extraordinary difficulties caused by a maturing population, the expanding expense of medicinal services, the priority given by the governments to bring down the cost of medications, boundaries to a passage in developing markets, and the more extensive reception of non-specific medications. These are quite recently a portion of the many difficulties making weight on the overall revenue of pharmaceutical firms. Expanded expenses of R&D and a diminished number of affirmed sedates additionally demonstrates that the lion's share of prescription, which is anything but difficult to find, has just been found.","PeriodicalId":243101,"journal":{"name":"Global Supply Chains in the Pharmaceutical Industry","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121547876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：